Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. rezolute is advancing a diversified pipeline including: rz358 (phase 2), an antibody for the ultra-orphan indication of congenital hyperinsulinism (chi) with an abbreviated path-to-market strategy; ab101 (phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and rz402 (plan to file ind in h2 2018), a plasma kallikrein inhibitor (pki) targeting diabetic macular edema (dme). for more information, visit: www.rezolutebio.com.
Select a linked metric to explore its chart.